Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Amortization of Deferred Charges (2021 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $398603.0 as the latest value for Q4 2022.

  • Quarterly Amortization of Deferred Charges fell 24.79% to $398603.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2022, down 76.36% year-over-year, with the annual reading at $79275.0 for FY2025, 2.22% down from the prior year.
  • Amortization of Deferred Charges hit $398603.0 in Q4 2022 for Kraig Biocraft Laboratories, up from $176276.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $2.1 million in Q3 2021 to a low of $174669.0 in Q2 2022.